Exenatide Featured in New Systematic Review on Reward Processing

A new publication involving exenatide appeared on October 14, 2026. The paper, titled "Effects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic review," was published in the journal Acta Neuropsychiatrica. Exenatide is noted in the review as one of the GLP-1 mono-agonists examined. The publication is listed as a systematic review, meaning it compiles and evaluates existing animal model studies on this topic. No specific findings, outcomes, or conclusions from the review have been detailed in the available event information. The review's scope covers reward processing research related to GLP-1 mono-agonists broadly, with exenatide among the compounds included in this category. As a systematic review, this type of publication typically aims to synthesize prior research rather than present new experimental data. Readers interested in the full scope and conclusions of this review should consult the original publication directly. For additional background on exenatide, including its regulatory status and general information, readers can refer to the compound overview.